Vitae Obtains Proof-Of-Mechanism Data For BACE Inhibition In Alzheimer’s
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Two programs partnered with Germany’s Boehringer Ingelheim are advancing, with a type 2 diabetes program moving into Phase II while a beta secretase inhibitor for Alzheimer’s demonstrates strong ability to decrease amyloid beta levels in the brain. Vitae went public in September, netting $48.4 million from its IPO.